Lysosomal storage disorders (LSDs) are genetic diseases caused by deficiency of activity of enzymes degrading substrates including glycolipids, glycosaminoglycans, and proteins (1) . With the development of therapies for several LSDs (for example, 2-6), detection of enzyme activity in dried blood spots (DBS) from newborns is of recent interest because of the potential benefits of early treatment. We have previously reported several enzyme assays of lysosomal enzymes that were developed in a multiplex format using tandem mass spectrometry (MS/MS) (7). Here we report results expanding the diagnostic portfolio to a 7-plex format including new assays for lysosomal enzymes tripeptidyl peptidase 1 (TPP1), -N-acetylglucosaminidase (NAGLU), and lysosomal -glucuronidase (GUSB). These are combined with previously reported assays for
mucopolysacharidoses (-iduronidase (IDUA) for MPS-I, iduronate-2-sulfatase (I2S) for MPS-II,

N-acetylgalactosamine-6-sulfatase (GALNS) for MPS-IVA, and N-acetylgalactosamine-4-
sulfatase (ARSB) for MPS-VI) (8).
TPP1 deficiency results in classic late infantile (type 2) neuronal ceroid lipofuscinosis (LINCL, also called Jansky-Bielschowsky disease) (9) . LINCL is an autosomal recessive disorder causing neurodegenerative disease with seizures, mental regression, visual loss, and shortened life expectancy (10) . Mucopolysaccharidoses are a group of diseases resulting from deficiency of enzymes degrading glycosaminoglycans (1) . MPS-IIIB (also called Sanfilippo B) (11, 12) is caused by deficient NAGLU. MPS-VII (Sly syndrome) (13) results from deficient GUSB.
Recent advances in enzyme replacement therapies (2-6) provide a strong motivation for the development of analytical methods allowing for the detection of newborns at risk of developing one of the treatable LSD's.
Tandem mass spectrometry (MS/MS) with electrospray ionization (ESI) has been shown to a robust and comprehensive platform for newborn screening of several inborn errors of metabolism in which biomarkers or enzymatic activities are measured (7, 14, 15) . We have previously reported multiplex MS/MS assays that targeted a portfolio of several LSDs and utilized flow injection for sample delivery to the mass spectrometer (16) (17) (18) (19) . A limitation of the flow injection approach is that sulfatase substrates undergo non-enzymatic cleavage to desulfated products in the heated ESI source of the mass spectrometer that interfere with the activity measurements. In parallel efforts, liquid chromatography in combination with MS/MS (HPLC-MS/MS) has been evaluated as an alternative method of enzyme activity analysis in DBS (20) (21) (22) (23) (24) (25) .
HPLC leads to separation of substrates from products prior to MS/MS, thus in-source cleavage is of no concern. HPLC requires fast analyte elution to be applicable in newborn screening.
Previous HPLC-MS/MS methods for LSDs require only ~2 min inject-to-inject times (20) (21) (22) (23) (24) (25) and are thus appropriate for newborn screening.
Methods
Experimental details of the reported assays and synthetic procedures are given as supplementary text, schemes and tables. DBS were obtained from the Washington newborn screening laboratory with Institutional Review Board approval.
Results
The reported method utilizes substrates and internal standards for IDUA, I2S, GALNS, and ARSB that have been reported previously (8, 26) . The previously reported substrate (S) and internal standard (IS) for TPP1 (27) have been modified by replacing the C3 linker with a longer C6 aliphatic chain (Figure 1 ) with the goal of increasing the product and IS hydrophobicity (to increase retention to the LC column). Details of the synthetic procedures and compound characterization are described in the Supplement. Action of the TPP1 enzyme results in benzylamide bond cleavage releasing the product (TPP1-P). The Ala-Ala-Phe tripeptide motif was selected because it is a preferred natural target of TPP1 (28) and has been shown to give high activity in in vitro assays (27) . The TPP1 enzyme activity towards the new substrate was fully characterized by incubations in DBS. The activity (mol hour -1 L blood -1 ) showed a linear increase with the substrate concentration up to 800 M (Supplemental Figure 1) and incubation time over a 24 hour period (Supplemental Figure 2) . The TPP1 activity varied between pH 3.5-6 but did not show a prominent pH-dependent trend within this range (Supplemental Figure 3) . The internal standard (TPP-IS) is chemically identical to TPP1-P but is distinguished by a 9 Da mass difference due to the presence of the d9-tert-butyl group.
The previously reported NAGLU substrate (NAGLU-S) and internal standard (NAGLU-IS) (29) were redesigned to be suitable for multiplex analysis of MPS IIIB. The new compounds ( Figure 1 ) were synthesized and characterized as described in the Supplement. Action of NAGLU results in hydrolysis of the glycosidic bond in NAGLU-S forming the aglycone which is the enzyme product (NAGLU-P). The new NAGLU aglycon scaffold consists of an acylated aminophenol with a six-carbon linker between a tertiary C5 and secondary C3 amide group. The tertiary amide is presumably involved in facile protonation in electrospray (30) , whereas the C5 and C3 amides provide a mass encoding combination for MS/MS and tune the product hydrophobicity for fast HPLC elution. The NAGLU-IS is a d5-derivative of NAGLU-P with the label in the C3-amide group that is retained in the reporter fragment ion in MS/MS.
The GUSB substrate is analogous to that for NAGLU in the composition of the aglycone but differs from it by being a -glucoside and having a C4 secondary amide ( Figure 1 ). Action of the GUSB enzyme hydrolyzes the glycosidic bond producing the aglycone as GUSB-P. GUSB-IS is a d7-derivative that has the isotope label in the C4 amide group.
The NAGLU and GUSB activities towards the new substrates were fully characterized as a function of the incubation time, substrate concentration, and pH, as described in the Supplement ( Figures S4-S9 ). The NAGLU and GUSB had optimum activities at pH 5.0 ( Figure S4 ) and 4.1 ( Figure S9 ), respectively. With regard to the previously determined optimum pH for the other enzyme substrates (22, 26) , the multiplex assay pH was adjusted to pH 5.0 to assure that all seven enzymes had activity within a sufficient analytical range, with a particular regard to the least active GALNS (8) . The sufatases are inhibited by inorganic phosphate and sulfate that has to be sequestered from the assay medium (22) . This is achieved by precipitating sulfate and phosphate with added cerium(III)sulfate at 5 mM concentration during the incubation (22) .
The assays were performed in 96-well microtiter plates in 50 mM ammonium acetate buffer MS/MS measurements were performed in a multiple reaction monitoring (MRM) format on a Waters Xevo TQMS tandem quadrupole mass spectrometer equipped with an Acquity UPLC separation system (an HPLC system is adequate). Experimental conditions including cone voltages and laboratory collision energies were optimized for each parent ion-fragment ion transition. The transition m/z for products and internal standards show no overlaps (Supplemental Table S1 ), ensuring independent determination of enzyme activities in the multiplex format. The HPLC traces for all product MRM transitions are shown in Figure 2 , the analogous traces for the IS are presented in Supplemental Figure S10 . The HPLC-MRM traces show two types of signals.
One type corresponds to MRM transitions associated with elution of the enzymatic products produced by DBS incubation at their specific retention times. The product retention times coincide with those of the internal standards that are distinguished by different m/z because of deuteration (Table S1 ). The other signals correspond to elution of residual substrates that underwent partial non-enzymatic dissociation in the hot ESI source of the mass spectrometer, forming gas-phase ions identical with those from products of enzyme incubation. Since the assays are generally run at low substrate conversion, the substrates are major components of the mixture injected on the column. We have also examined HPLC separations on reverse-phase C-18 monolith columns (EMD Chromolith, Fast Gradient, RP18e, 50-2 mm, sorbent lot/column No. U11509/101). When using a well-conditioned column, we were able to obtain satisfactory separation of I2S, NAGLU, GALNS, and ARSB products and internal standards. However, new columns from the supplier required very long (36 h) conditioning to achieve satisfactory separation of the substrates and products or internal standards. The use of Chromolith columns was therefore less preferred.
The activities measured for DBS from 62 unaffected infants are visualized in violin plots (Figure 3 -5) and summarized in Table 1 (individual values given in Suppl. and 757 for GALNS, NAGLU, ARSB, I2S, GUSB, and TPP1, respectively.
In our previous study of TPP1 assays (27) we noted a decreased TPP1 activity in samples that were stored at room temperature for long periods. Enzyme stability in DBS is an important issue that has been addressed previously for five lysosomal enzymes (31) . We studied the activities of TPP1, NAGLU, and GUSB in DBS that were obtained by a fresh blood prick and then stored in ziplock bags at -20 °C, 4 °C, and ambient temperature for up to 34 days. The TPP1 activity showed a 25-30% decrease over 34 days at all storage temperatures (Supplementary Figure S11) .
The NAGLU and GUSB activities showed ~15-20% decreases ( Supplementary Figures S12 and   S13 ). However, the activity data measurements performed on different days showed some scatter that made extrapolation to longer times uncertain. The data indicate that DBS storage at -20 °C for a few months is unlikely to degrade TPP1, NAGLU, and GUSB to affect enzyme activity measurements for healthy individuals. DBS aging and degradation may affect measurements for samples with activities close to the level cutoffs by increasing the number of false positives.
IDUA for analysis of MPS-I is typically done as part of a 6-plex LSD newborn screening assay (15, 32) . We found that the IDUA substrate could be added to the above assay cocktail so that the full set of mucopolysaccharidoses could be analyzed in a single multiplex run. The detailed experimental protocol, HPLC-MS/MS traces, and a typical data set are shown in Suppl.
Material. The analytical range for IDUA was > 100.
DISCUSSION
The results from the multiplex LC-MS/MS assay show a very good separation of enzyme activities in DBS from the normal cohort and affected patients. The Figure 3 data for TPP1 indicate that the activities in the DBS from the LINCL patients are significantly lower than the lowest normals and also lower than the activities from patients affected by the other LSD. Similar results are shown in Figure 4 where the DBS from the MPS IIIB affected patients showed virtually zero NAGLU activities. The results for GUSB ( Figure 5 ) are also conclusive in showing a large separation of the activities in DBS from the MPS VII affected patients from the rest of the set. An added benefit of multiplexing the assay is that a finding of simultaneously low activities for 2 or more lysosomal enzymes can be an indication that the integrity of the DBS sample has been compromised. Also, multiplexing methods are amenable to statistical methods in which covariances are used to determine screen positive scores rather than absolute cutoff values (14) .
The analytical ranges of the 7 assays are more than 1-to 2-orders of magnitude higher than those of fluorometric assays with 4-methylumbelliferone substrates (8) . For example, the analytical range of the HPLC-MS/MS assay for GALNS of 909 is 360-fold higher than the value of ~2-3 reported for the fluorimetric assay using DBS and the 4-methylumbelliferone substrate (33, 34) . High analytical ranges of the MS/MS assays are predicted to yield a lower number of false positives compared to fluorometric assays when applied to newborn screening of LSDs as has been observed from large scale pilot studies and live newborn screening reports (7) . Also, it
is not possible with the fluorometric assays to accurately measure relatively low amounts of residual lysosomal enzymes for post-newborn screening diagnosis and prognosis studies, whereas MS/MS assays provide clear stratification of these samples (35) (36) (37) . The relatively low analytical ranges for the fluorometric assays are due to the fact that the substrate itself is fluorescent and thus significantly contributes to the blank (8) .
As an alternative to direct measurement of lysosomal enzymes in DBS, MS/MS analysis of accumulated glycosaminoglycan (measured as disaccharide degradation products) has been suggested as a first-tier newborn screening analysis of the mucopolysaccharidoses (38) . It is thus In marked contrast, the pilot study of the enzymatic analysis method described here (being carried out in the WA newborn screening laboratory, M.H. Gelb and C. R. Scott, unpublished) on the first glycosaminoglycan method). The screen positive rate increases to 0.045% if all 7 mucopolysaccharidoses are considered. These results suggest that the enzymatic activity assay should be carried out for first-tier newborn screening with glycosaminoglycan analysis used as a possible second-tier assay; this is the method currently being used for newborn screening of MPS-I in the KY state newborn screening lab.
Studies are underway to test these new HPLC-MS/MS enzymatic assays for diagnostic and prognostic purposes using leukocytes as the enzyme source rather than DBS. It is hoped that the large analytical range will lead to a separation of affected individuals from those with pseudodeficiencies as well as to estimate the severity of the disease, for example early versus late onset forms. Table S1 (there are no isobaric overlaps for all P and IS). S → P indicates product ions formed by decomposition of the substrates in the ion source. Figure 3 . TPP1 activity distributions in DBS from the random newborn cohort (NB), quality controls (QC), and affected patients (PT) showing the medians (°), interquantile-range (iqr, q3-q1) (|) and range of (q1-1.5iqr: q3+1.5iqr) except when it is beyond the boundary of the data (). Figure 4 . NAGLU activity distributions in DBS from the random newborn cohort (NB), quality controls (QC), and affected patients (PT) showing the medians (°), interquantile-range (iqr, q3-q1) (|) and range of (q1-1.5iqr: q3+1.5iqr) except when it is beyond the boundary of the data (). Figure 5 . GUSB activity distributions in DBS from the random newborn cohort (NB), quality controls (QC), and affected patients (PT) showing the medians (°), interquantile-range (iqr, q3-q1) (|) and range of (q1-1.5iqr: q3+1.5iqr) except when it is beyond the boundary of the data ().
